- hypersensitivity to darunavir, cobicistat, or any excipients - patients with severe liver injury (child-pugh class c) - concomitant medications that are highly dependent on cyp3a clearance, and the elevated plasma concentrations are associated with serious or life-threatening events. - subjects were considered to be unable to complete the study, or not suitable for the study by researchers exit criteria: - subjects asked to withdraw the study - subject will benefit if withdraw according to researchers' suggestions

- hypersensitivity to darunavir, cobicistat, or any excipients - patients with severe liver injury (child-pugh class c) - concomitant medications that are highly dependent on cyp3a clearance, and the elevated plasma concentrations are associated with serious or life-threatening events. - subjects were considered to be unable to complete the study, or not suitable for the study by researchers exit criteria: - subjects asked to withdraw the study - subject will benefit if withdraw according to researchers' suggestions